Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients

Le résumé fourni par la source

Abstract Purpose Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin lymphoma and NK/T cell lymphoma. This study aimed to evaluate the real-world efficacy and safety of PD-1 antibody monotherapy or combination therapy in pediatric lymphoma patients. Methods From March 1, 2017, to October 25, 2022, we retrospectively analyzed data from 41 pediatric lymphoma patients who received PD-1 antibody treatment, including those with Hodgkin lymphoma, extranodal NK/T cell lymphoma, primary mediastinal large B-cell lymphoma, and other subtypes. Kaplan–Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Descriptive statistics were used to report response rates and adverse effects. Results The median follow-up period was 22.4 months (range, 1.3–67.6 months), and the overall response rate for the entire cohort was 82.9% (51.2% complete response [CR], 31.7% partial response [PR]). Only two patients died due to disease progression. The two-year PFS rate was 63.0 ± 8.5%, and the median OS and PFS were not reached. PD-1 antibodies were generally well tolerated, particularly in patients receiving monotherapy. Conclusion Our findings suggest that PD-1 antibody treatment offers a high response rate and low toxicity in pediatric lymphoma patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.